US Patent

US10912781 — Pharmaceutical composition comprising licarbazepine acetate

Formulation · Assigned to Bial Portela and Cia SA · Expires 2028-10-23 · 2y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition containing licarbazepine acetate, especially eslicarbazepine acetate, in combination with excipients and a granulation process for making it.

USPTO Abstract

A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition.

Drugs covered by this patent

Patent Metadata

Patent number
US10912781
Jurisdiction
US
Classification
Formulation
Expires
2028-10-23
Drug substance claim
No
Drug product claim
Yes
Assignee
Bial Portela and Cia SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.